Rose McNulty

Regeneron’s PD-1 inhibitor Libtayo was accepted for priority FDA review for the treatment of first-line locally advanced or metastatic non–small cell lung cancer (NSCLC) with PD-L1 expression of at least 50%.

A recent analysis identified disparities in the start of breast cancer treatment and the duration of treatment in Black women compared with White women.

Current screening criteria in the United States identify fewer women than men who will get lung cancer, creating a perfect storm for what experts during a session at the CHEST Annual Meeting deemed an “invisible epidemic.”

A pair of abstracts based on a phase 1/2 trial of adagrasib (MRTX849) a KRAS G12C inhibitor, showed promising results for patients with lung, bowel, and other solid tumors, researchers reported at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.

A study published in the Journal of Clinical Oncology determined that the main risk factor for breast cancer-related lymphedema in patients with positive axillary lymph nodes is the type of axillary surgery used.

During a session on day 1 of the Community Oncology Alliance (COA) Virtual Payer Exchange Summit on Oncology Payment Reform, a panel of experts discussed the ways COVID-19 continues to impact cancer care and payment reform.

Lucio Gordan, MD, president and managing physician at Florida Cancer Specialists and Research Institute, discusses the impact that COVID-19 continues to have on health care delivery and payment reform initiatives as the COA Payer Exchange Summit tackles this and other issues in payment reform.

Bo Gamble, director of Strategic Practice Initiatives for the Community Oncology Alliance (COA), previewed the COA Payer Exchange Summit on Oncology Payment Reform ahead of the 2-day virtual meeting on October 27-28, 2020.

During the upcoming Community Oncology Alliance (COA) Payer Exchange Summit, a panel discussion on applying value-based insurance design (VBID) in oncology will explore ways in which the coronavirus disease 2019 crisis can be an opportunity for growth.

Researchers analyzed 2 randomized studies to learn how adding radiation therapy to pembrolizumab immunotherapy affects non-small cell lung cancer patient outcomes.

Experts in cancer care and payment discussed the future of oncology care in a panel discussion hosted by Avalere Health on October 21, 2020.

Cancer screenings and treatments saw a sharp decline during the early months of the pandemic. The authors of a new study on the delays in care warn that the fallout may be grim.

A new analysis predicts close to 3000 additional deaths over a 10-year period in patients who faced delays in breast cancer treatment during the pandemic.

Two abstracts presented at the Migraine Trust Virtual Symposium investigated lasmiditan’s safety in elderly and pediatric migraine patients.

A study and accompanying editorial from the Journal of Clinical Oncology found that Hodgkin lymphoma survivors still face a higher risk of non-cancer death than the general population.

Findings suggest that current standard treatment does not eliminate the risk of breast cancer-specific death in the 20 years after DCIS diagnosis.

Natera’s Signatera ctDNA test will determine study eligibility and treatment effectiveness in HR-positive, HER2-negative breast cancer patients.

Research from the American Cancer Society suggests that more young people are being introduced to nicotine via e-cigarettes.